Imaging of advanced neuroendocrine tumors with 18F-FDOPA PET

A Becherer, M Szabó, G Karanikas… - Journal of Nuclear …, 2004 - Soc Nuclear Med
Nuclear medicine plays an important role in the imaging of neuroendocrine tumors (NETs).
Somatostatin receptor scintigraphy (SRS) with 111In-labeled somatostatin receptor analogs …

[HTML][HTML] Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine …

RP Baum, HR Kulkarni, A Singh, D Kaemmerer… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Methods In our center, 2294 patients were screened between 2004 and 2014 by 68 Ga
somatostatin receptor (SSTR) PET/CT. Intention to treat analysis included 1048 patients …

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors

TD Poeppel, I Binse, S Petersenn… - Journal of nuclear …, 2011 - Soc Nuclear Med
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and
therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of …

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET

T Binderup, U Knigge, A Loft, J Mortensen… - Journal of Nuclear …, 2010 - Soc Nuclear Med
Functional techniques are playing a pivotal role in the imaging of cancer today. Our aim was
to compare, on a head-to-head basis, 3 functional imaging techniques in patients with …

68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial

ECS de Camargo Etchebehere… - Journal of Nuclear …, 2014 - Soc Nuclear Med
There are different metabolic imaging methods, various tracers, and emerging anatomic
modalities to stage neuroendocrine tumor (NET). We aimed to compare NET lesion …

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide

DJ Kwekkeboom, EP Krenning, K Scheidhauer… - …, 2009 - karger.com
Dik J. Kwekkeboom a Eric P. Krenning a Klemens Scheidhauer b Val Lewington c Rachida
Lebtahi d Ashley Grossman e Pavel Vitek f Anders Sundin g Ursula Plöckinger h and the …

[HTML][HTML] Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga …

MÖ Öksüz, L Winter, C Pfannenberg, G Reischl… - Diagnostic and …, 2014 - Elsevier
Abstract Purpose PET with 68 Ga-DOTATOC allows for imaging and quantitative
assessment of somatostatin receptor expression in neuroendocrine tumors (NET). The aim …

[HTML][HTML] Whole-body 68Ga-DOTANOC PET/MRI versus 68Ga-DOTANOC PET/CT in patients with neuroendocrine tumors: a prospective study in 28 patients

D Berzaczy, C Giraudo, AR Haug… - Clinical nuclear …, 2017 - journals.lww.com
Purpose The aim of this study was to assess the diagnostic performance of simultaneous
whole-body 68 Ga-DOTANOC PET/MRI compared with 68 Ga-DOTANOC PET/CT for …

Peptide receptor radionuclide therapy

J Hofland, T Brabander, FA Verburg… - The Journal of …, 2022 - academic.oup.com
The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …

The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours

PG Hillel, EJR Van Beek, C Taylor, E Lorenz, NDS Bax… - Clinical radiology, 2006 - Elsevier
AIM: With a combined gamma camera/CT imaging system, CT images are obtained which
are inherently registered to the emission images and can be used for the attenuation …